Alison Hume Alert Sample


Alert Sample

View the Parallel Parliament page for Alison Hume

Information between 6th January 2026 - 16th January 2026

Note: This sample does not contain the most recent 2 weeks of information. Up to date samples can only be viewed by Subscribers.
Click here to view Subscription options.


Division Votes
13 Jan 2026 - Finance (No. 2) Bill - View Vote Context
Alison Hume voted Aye - in line with the party majority and in line with the House
One of 323 Labour Aye votes vs 0 Labour No votes
Tally: Ayes - 348 Noes - 167
13 Jan 2026 - Finance (No. 2) Bill - View Vote Context
Alison Hume voted No - in line with the party majority and in line with the House
One of 325 Labour No votes vs 0 Labour Aye votes
Tally: Ayes - 181 Noes - 335
13 Jan 2026 - Finance (No. 2) Bill - View Vote Context
Alison Hume voted Aye - in line with the party majority and in line with the House
One of 328 Labour Aye votes vs 0 Labour No votes
Tally: Ayes - 344 Noes - 173
13 Jan 2026 - Finance (No. 2) Bill - View Vote Context
Alison Hume voted No - in line with the party majority and in line with the House
One of 334 Labour No votes vs 0 Labour Aye votes
Tally: Ayes - 187 Noes - 351
13 Jan 2026 - Finance (No. 2) Bill - View Vote Context
Alison Hume voted No - in line with the party majority and in line with the House
One of 328 Labour No votes vs 0 Labour Aye votes
Tally: Ayes - 172 Noes - 334
13 Jan 2026 - Finance (No. 2) Bill - View Vote Context
Alison Hume voted No - in line with the party majority and in line with the House
One of 321 Labour No votes vs 0 Labour Aye votes
Tally: Ayes - 184 Noes - 331
12 Jan 2026 - Finance (No. 2) Bill - View Vote Context
Alison Hume voted No - in line with the party majority and in line with the House
One of 338 Labour No votes vs 0 Labour Aye votes
Tally: Ayes - 167 Noes - 350
12 Jan 2026 - Finance (No. 2) Bill - View Vote Context
Alison Hume voted No - in line with the party majority and in line with the House
One of 333 Labour No votes vs 0 Labour Aye votes
Tally: Ayes - 188 Noes - 341
12 Jan 2026 - Finance (No. 2) Bill - View Vote Context
Alison Hume voted Aye - in line with the party majority and in line with the House
One of 336 Labour Aye votes vs 0 Labour No votes
Tally: Ayes - 344 Noes - 181
12 Jan 2026 - Finance (No. 2) Bill - View Vote Context
Alison Hume voted No - in line with the party majority and in line with the House
One of 336 Labour No votes vs 0 Labour Aye votes
Tally: Ayes - 185 Noes - 344
14 Jan 2026 - Public Order - View Vote Context
Alison Hume voted Aye - in line with the party majority and in line with the House
One of 295 Labour Aye votes vs 26 Labour No votes
Tally: Ayes - 301 Noes - 110
12 Jan 2026 - Clause 1 - View Vote Context
Alison Hume voted No - in line with the party majority and in line with the House
One of 332 Labour No votes vs 0 Labour Aye votes
Tally: Ayes - 188 Noes - 341
12 Jan 2026 - Clause 1 - View Vote Context
Alison Hume voted No - in line with the party majority and in line with the House
One of 338 Labour No votes vs 0 Labour Aye votes
Tally: Ayes - 167 Noes - 350
12 Jan 2026 - Clause 1 - View Vote Context
Alison Hume voted No - in line with the party majority and in line with the House
One of 335 Labour No votes vs 0 Labour Aye votes
Tally: Ayes - 185 Noes - 344
12 Jan 2026 - Clause 1 - View Vote Context
Alison Hume voted Aye - in line with the party majority and in line with the House
One of 335 Labour Aye votes vs 0 Labour No votes
Tally: Ayes - 344 Noes - 181


Speeches
Alison Hume speeches from: Business of the House
Alison Hume contributed 1 speech (78 words)
Thursday 15th January 2026 - Commons Chamber
Leader of the House


Written Answers
Genomics
Asked by: Alison Hume (Labour - Scarborough and Whitby)
Friday 9th January 2026

Question to the Department for Science, Innovation & Technology:

To ask the Secretary of State for Science, Innovation and Technology, what plans her Department has to support the use of combinatorial genomic analysis techniques, such as those used by Precision Life to identify novel ME genetic associations, within government-funded research programmes.

Answered by Kanishka Narayan - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)

The Medical Research Council (MRC), which is part of UK Research and Innovation (UKRI), funds a broad portfolio of health research, including researcher led proposals using combinatorial genomic analysis. MRC has prioritised research into Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) for many years, investing over £4.65 million since 2020, and continues to welcome high quality applications in this area.

UKRI supports collaboration between Government funded bodies and private sector researchers across its councils and Innovate UK. This includes funding the LOCOME study led by Precision Life, through Innovate UK’s Advancing Precision Medicine programme, which supports the development of digital and data tools to improve diagnosis and treatment. MRC also enables academic-industry partnerships through its Industry Collaboration Framework.

UKRI does not typically maintain disease‑specific research strategies, instead providing open funding routes for the most impactful research across disciplines. Targeted work can be supported where needed. For example, in 2020, the National Institute for Health and Care Research (NIHCR), the Scottish Government and MRC funded the James Lind Alliance Priority Setting Partnership to identify ME/CFS research priorities.

Genomics
Asked by: Alison Hume (Labour - Scarborough and Whitby)
Friday 9th January 2026

Question to the Department for Science, Innovation & Technology:

To ask the Secretary of State for Science, Innovation and Technology, what plans her Department has to develop a long-term research strategy into under-researched health conditions that reflects the scale of emerging genetic evidence identified by private-sector research organisations, including Precision Life’s LOCOME study.

Answered by Kanishka Narayan - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)

The Medical Research Council (MRC), which is part of UK Research and Innovation (UKRI), funds a broad portfolio of health research, including researcher led proposals using combinatorial genomic analysis. MRC has prioritised research into Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) for many years, investing over £4.65 million since 2020, and continues to welcome high quality applications in this area.

UKRI supports collaboration between Government funded bodies and private sector researchers across its councils and Innovate UK. This includes funding the LOCOME study led by Precision Life, through Innovate UK’s Advancing Precision Medicine programme, which supports the development of digital and data tools to improve diagnosis and treatment. MRC also enables academic-industry partnerships through its Industry Collaboration Framework.

UKRI does not typically maintain disease‑specific research strategies, instead providing open funding routes for the most impactful research across disciplines. Targeted work can be supported where needed. For example, in 2020, the National Institute for Health and Care Research (NIHCR), the Scottish Government and MRC funded the James Lind Alliance Priority Setting Partnership to identify ME/CFS research priorities.

Chronic Fatigue Syndrome: Research
Asked by: Alison Hume (Labour - Scarborough and Whitby)
Friday 9th January 2026

Question to the Department for Science, Innovation & Technology:

To ask the Secretary of State for Science, Innovation and Technology, what mechanisms are in place to support collaboration between Government-funded bodies and private-sector researchers following the identification of multiple biological pathways implicated in ME by the LOCOME study.

Answered by Kanishka Narayan - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)

The Medical Research Council (MRC), which is part of UK Research and Innovation (UKRI), funds a broad portfolio of health research, including researcher led proposals using combinatorial genomic analysis. MRC has prioritised research into Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) for many years, investing over £4.65 million since 2020, and continues to welcome high quality applications in this area.

UKRI supports collaboration between Government funded bodies and private sector researchers across its councils and Innovate UK. This includes funding the LOCOME study led by Precision Life, through Innovate UK’s Advancing Precision Medicine programme, which supports the development of digital and data tools to improve diagnosis and treatment. MRC also enables academic-industry partnerships through its Industry Collaboration Framework.

UKRI does not typically maintain disease‑specific research strategies, instead providing open funding routes for the most impactful research across disciplines. Targeted work can be supported where needed. For example, in 2020, the National Institute for Health and Care Research (NIHCR), the Scottish Government and MRC funded the James Lind Alliance Priority Setting Partnership to identify ME/CFS research priorities.

Chronic Fatigue Syndrome and Long Covid: Health Services
Asked by: Alison Hume (Labour - Scarborough and Whitby)
Wednesday 14th January 2026

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department will be assessing the impact of new developments in Myalgic Encephalomyelitis and Long Covid research, such as the findings of the LOCOME project, on health policy towards those living with long term health conditions.

Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)

On 6 November, the National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC) jointly hosted a showcase event for post-acute infection conditions research, which included a review of the DecodeME research project and the PrecisionLife study on myalgic encephalomyelitis (ME) and long COVID research. PrecisionLife is leading on the LOCOME, or LOng COvid and Myalgic Encephalomyelitis Diagnostics Stratification, project. The showcase event was attended by speakers from a range of disciplines, including researchers, people with lived experience, ME charities, NIHR and MRC representatives, as well as Government officials.

The Department is always very keen to reflect newly emerging research findings in its policy-making.



MP Financial Interests
5th January 2026
Alison Hume (Labour - Scarborough and Whitby)
1.1. Employment and earnings - Ad hoc payments
Payment received on 18 November 2025 - £216.53
Source



Alison Hume mentioned

Select Committee Documents
Tuesday 13th January 2026
Oral Evidence - 2026-01-13 16:15:00+00:00

Proposals for backbench debates - Backbench Business Committee

Found: the meeting Members present: Bob Blackman (Chair); Jonathan Davies; Mr Lee Dillon; Mary Glindon; Alison Hume

Monday 12th January 2026
Special Report - 7th Special Report - Airport expansion and climate and nature targets: Government Response

Environmental Audit Committee

Found: Conservative; Bognor Regis and Littlehampton) Chris Hinchliff (Labour; North East Hertfordshire) Alison Hume




Alison Hume - Select Committee Information

Calendar
Tuesday 13th January 2026 4 p.m.
Backbench Business Committee - Oral evidence
Subject: Proposals for backbench debates
At 4:15pm: Oral evidence
Members of Parliament - Members of Parliament at House of Commons
View calendar - Add to calendar
Tuesday 20th January 2026 4 p.m.
Backbench Business Committee - Oral evidence
Subject: Proposals for backbench debates
At 4:15pm: Oral evidence
Members of Parliament - Members of Parliament at House of Commons
View calendar - Add to calendar
Tuesday 27th January 2026 4 p.m.
Backbench Business Committee - Oral evidence
Subject: Proposals for backbench debates
At 4:15pm: Oral evidence
Members of Parliament - Members of Parliament at House of Commons
View calendar - Add to calendar
Tuesday 3rd February 2026 4 p.m.
Backbench Business Committee - Oral evidence
Subject: Proposals for backbench debates
At 4:15pm: Oral evidence
Members of Parliament - Members of Parliament at House of Commons
View calendar - Add to calendar


Select Committee Documents
Tuesday 6th January 2026
Oral Evidence - 2026-01-06 16:15:00+00:00

Proposals for backbench debates - Backbench Business Committee
Tuesday 13th January 2026
Oral Evidence - 2026-01-13 16:15:00+00:00

Proposals for backbench debates - Backbench Business Committee
Tuesday 20th January 2026
Oral Evidence - 2026-01-20 16:15:00+00:00

Proposals for backbench debates - Backbench Business Committee
Tuesday 27th January 2026
Oral Evidence - 2026-01-27 16:15:00+00:00

Proposals for backbench debates - Backbench Business Committee